CORONA Remedies Limited (NSE:CORONA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Pharmaceuticals	14.03B	11.96B	10.14B	8.84B	6.17B
Total	14.03B	11.96B	10.14B	8.84B	6.17B

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
India	13.46B	11.52B	9.80B	8.52B	5.95B
outside India	569.10M	439.60M	342.46M	318.89M	221.88M
Total	14.03B	11.96B	10.14B	8.84B	6.17B

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 23, 2026

Data Sources Report a data error